Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis

OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Altered lymphocyte cell counts and a potential association with increased infection rates have been reported in RA patients treated with JAK inhibitors. This analysis was undertaken to evaluate the short‐...

Descripción completa

Detalles Bibliográficos
Autores principales: van Vollenhoven, Ronald, Lee, Eun Bong, Strengholt, Sander, Mojcik, Christopher, Valdez, Hernan, Krishnaswami, Sriram, Biswas, Pinaki, Lazariciu, Irina, Hazra, Anasuya, Clark, James D., Hodge, Jennifer, Wang, Lisy, Choy, Ernest
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593802/
https://www.ncbi.nlm.nih.gov/pubmed/30427585
http://dx.doi.org/10.1002/art.40780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593802/
https://www.ncbi.nlm.nih.gov/pubmed/30427585
http://dx.doi.org/10.1002/art.40780

Ejemplares similares